ALTIMMUNE, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $9.00K, a 125.00% increase year-over-year.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $13.00K, a 225.00% increase year-over-year.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $33.00K, a 76.26% decline year-over-year.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $4.00K, a 97.98% decline year-over-year.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $41.00K, a 90.66% decline from fiscal 2024.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $439.00K, a 288.50% increase from fiscal 2023.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $113.00K, a 88.11% decline from fiscal 2022.
- ALTIMMUNE, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $950.00K, a 439.77% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $9.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $13.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $41.00K 10-K · filed 2026-03-06 | |
| 2025-09-30 | $33.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $4.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $439.00K 10-K · filed 2026-03-06 | |
| 2024-09-30 | $139.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $198.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $9.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $113.00K 10-K · filed 2025-02-27 | |
| 2023-03-31 | $61.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $950.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $268.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $403.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $197.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $176.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | $6.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $94.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $128.90K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $90.27K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $36.17K 10-Q · filed 2021-11-09 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $22.90K 10-K · filed 2020-03-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $22.90K derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | $4.41K 10-Q · filed 2019-11-13 | |
| 2018-03-31 | $18.49K 10-Q · filed 2019-11-13 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $16.45K 10-K · filed 2019-04-01 |
| 2017-03-31 | $450.00 10-Q · filed 2018-05-15 | |
| 2016-12-31 | $563.00 10-K · filed 2018-04-02 | |
| 2015-12-31 | $973.13K 10-K · filed 2017-03-14 | |
| 2014-12-31 | $455.84K 10-K · filed 2017-03-14 | |
| 2013-12-31 | $74.80K 10-K · filed 2016-03-11 | |
| 2012-12-31 | $38.98K 10-K · filed 2015-03-11 | |
| 2011-12-31 | $118.31K 10-K · filed 2014-03-11 | |
| 2010-12-31 | $56.21K 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |